LUCA Science
Tokyo, Japan· Est.
A preclinical biotech developing functional mitochondria as therapeutic agents to treat diseases caused by cellular energy deficiency.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A preclinical biotech developing functional mitochondria as therapeutic agents to treat diseases caused by cellular energy deficiency.
Immunology
Technology Platform
Proprietary iMIT platform for isolating, formulating, storing, and delivering functional mitochondria as an off-the-shelf biopharmaceutical agent.
Opportunities
The platform technology addresses a fundamental mechanism (bioenergetics) with potential applications across a vast range of acute injuries, inherited disorders, and chronic degenerative diseases, representing a large and underserved market.
Risk Factors
As a preclinical company with a highly novel therapeutic modality, it faces significant technical risks in manufacturing, delivery, and clinical translation, as well as regulatory uncertainty for a first-in-class product.
Competitive Landscape
Competition is emerging but fragmented; LUCA aims to differentiate through its proprietary iMIT platform for producing a consistent, storable mitochondrial product, unlike many research-focused approaches.